Dr. Michael Mauro on Treatment Discontinuation for CML

Michael Mauro, MD
Published: Friday, Feb 20, 2015

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia (CML).

Treatment with a TKI can offer a “functional cure,” for some CML patients, said Mauro.  After a period of treatment, some patients may be able to discontinue TKI therapy.

If patients have a good response to therapy without any degree of relapse, lower-risk disease at presentation, and a period of time in a deep molecular remission, they may be a candidate for treatment discontinuation.  On average, about half of the patients that fit that criteria may be able to stop TKI therepy without having significant relapse.

<<< View more from the 2015 Congress on Hematologic Malignancies

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia (CML).

Treatment with a TKI can offer a “functional cure,” for some CML patients, said Mauro.  After a period of treatment, some patients may be able to discontinue TKI therapy.

If patients have a good response to therapy without any degree of relapse, lower-risk disease at presentation, and a period of time in a deep molecular remission, they may be a candidate for treatment discontinuation.  On average, about half of the patients that fit that criteria may be able to stop TKI therepy without having significant relapse.

<<< View more from the 2015 Congress on Hematologic Malignancies


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x